KMPH - ケムファ―ム （KemPharm Inc.） ケムファ―ムKMPHのチャート
KMPHの企業情報
| symbol | KMPH |
|---|---|
| 会社名 | KemPharm Inc （ケムファ―ム） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ケムファーム（KemPharm Inc.）は、新規分子実体（NME）プロドラッグの発見・開発に従事する米国の臨床段階特殊医薬品会社である。同社は、自社リガンド活性化療法（LAT）プラットフォーム技術を通じて、NMEプロドラッグ製品候補の作成を行う。そのNMEプロドラッグ製品候補は疼痛治療用KP201/APAP、KP511/ERとKP606/ER、注意欠陥多動性障害（ADHD）治療用KP415、及び中枢神経系（CNS）障害治療用KP303を含む。KP201/APAPは臨床試験段階にあり、KP511/ER、KP415、KP606/ER及びKP303は前臨床試験段階にある。 ケムファ―ムは、米国の製薬会社。リガンド活性化療法を採用し、処方・承認薬を向上させる独自のプロドラッグの発見と開発に従事。おもな製品候補として、急性および中程度から重度の疼痛の治療薬であるKP201/APAP(ヒドロコドンとアセトアミノフェンから構成される)の開発を手掛ける。 KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LAT™ technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm's prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder. KemPharm's co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration/effect profiles. In addition, KemPharm has received FDA approval for APADAZ®, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. |
| 本社所在地 | 2500 Crosspark Road Suite E126 Coralville IA 52241 USA |
| 代表者氏名 | Travis C. Mickle トラビス・ミクル |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
| 電話番号 | +1 319-665-2575 |
| 設立年月日 | 38991 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2015年 |
| 従業員数 | － |
| url | www.kempharm.com |
| nasdaq_url | https://www.nasdaq.com/symbol/kmph |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -46.10100 |
| 終値（lastsale） | 2.61 |
| 時価総額（marketcap） | 41869666.98 |
| 時価総額 | 時価総額（百万ドル） 60.83858 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 123.47358 |
| 当期純利益 | 当期純利益（百万ドル） -56.75900 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 KemPharm Inc revenues was not reported. Net loss increased 59% to $36.2M. Higher net loss reflects Fair value adjustment related to derivat increase of 13% to $4.2M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.56 to -$2.42. |
KMPHのテクニカル分析
KMPHのニュース
KemPharm Files Preliminary Proxy 2023/02/27 21:32:07 Investing.com
https://www.investing.com/news/assorted/kempharm-files-preliminary-proxy-432SI-3016191
KemPharm Announces Arimoclomol Research Featured in Two Poster Presentations 2023/02/24 12:32:01 Investing.com
https://www.investing.com/news/assorted/kempharm-announces-arimoclomol-research-featured-in-two-poster-presentations-432SI-3013822
Zevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium 2023 2023/02/24 12:30:00 Wallstreet:Online
Interim data analysis of four-year, open-label extension from Phase 2/3 clinical trial suggests arimoclomol may reduce long-term progression of Niemann-Pick Disease Type C (NPC) CELEBRATION, Fla., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (“Zevra” or the “Company,” formerly known as KemPharm, Inc.), today announced that arimoclomol, the Company’s orally-delivered,
KemPharm (KMPH): Now A Rare Disease Play, Upgrading To A Buy Rating 2023/02/03 15:03:44 Seeking Alpha
We initiated KemPharm with a Sell rating in March 2021; since then, the stock has declined +40%, and now the stock is trading at an attractive enterprise value of $130m. Read more here.
Can you now get a good deal on KemPharm Inc.’s shares? 2023/01/25 16:40:00 US Post News
KemPharm Inc. (NASDAQ:KMPH) marked $5.61 per share on Tuesday, down from a previous closing price of $6.27. While KemPharm Inc. has underperformed by -10.53%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, KMPH fell by -13.43%, with highs and lows ranging from $7.38 to $4.00, whereas […]
KemPharm Files Preliminary Proxy 2023/02/27 21:32:07 Investing.com
https://www.investing.com/news/assorted/kempharm-files-preliminary-proxy-432SI-3016191
KemPharm Announces Arimoclomol Research Featured in Two Poster Presentations 2023/02/24 12:32:01 Investing.com
https://www.investing.com/news/assorted/kempharm-announces-arimoclomol-research-featured-in-two-poster-presentations-432SI-3013822
Zevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium 2023 2023/02/24 12:30:00 Wallstreet:Online
Interim data analysis of four-year, open-label extension from Phase 2/3 clinical trial suggests arimoclomol may reduce long-term progression of Niemann-Pick Disease Type C (NPC) CELEBRATION, Fla., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (“Zevra” or the “Company,” formerly known as KemPharm, Inc.), today announced that arimoclomol, the Company’s orally-delivered,
KemPharm (KMPH): Now A Rare Disease Play, Upgrading To A Buy Rating 2023/02/03 15:03:44 Seeking Alpha
We initiated KemPharm with a Sell rating in March 2021; since then, the stock has declined +40%, and now the stock is trading at an attractive enterprise value of $130m. Read more here.
Can you now get a good deal on KemPharm Inc.’s shares? 2023/01/25 16:40:00 US Post News
KemPharm Inc. (NASDAQ:KMPH) marked $5.61 per share on Tuesday, down from a previous closing price of $6.27. While KemPharm Inc. has underperformed by -10.53%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, KMPH fell by -13.43%, with highs and lows ranging from $7.38 to $4.00, whereas […]
KemPharm''s Lead Prodrug Shows Favorable Safety Profile For Rare Sleeping Disorder 2022/09/28 16:07:20 Benzinga
Full story available on Benzinga.com
KMPH stock on watch after Phase 1 data supporting sleep disorder therapy (NASDAQ:KMPH) 2022/09/28 12:45:11 Seeking Alpha
KemPharm, Inc. (KMPH), a company developing prodrug versions of FDA-approved drugs, announced Wednesday early results from a Phase 1 trial to support further studies for lead asset…
US Stocks Turn Lower; Nasdaq Drops Over 100 Points 2022/09/15 16:04:09 Benzinga
U.S. stocks turned lower midway through trading, with the Nasdaq Composite dropping more than 100 points on Thursday. The Dow traded down 0.12% to 31,099.20 while the NASDAQ fell 1.18% to 11,581.65. The S&P 500 also fell, dropping, 0.71% to 3,918.10. Also check this: Ethereum Records Gains; Here Are The Top Crypto Movers For Thursday Leading and Lagging Sectors Health care shares climbed 0.7% on Thursday. Meanwhile, top gainers in the sector included Armata Pharmaceuticals, Inc. (NYSE: ARMP ), up 10% and KemPharm, Inc. (NASDAQ: KMPH ) up 9%. In trading on Thursday, information technology shares fell by 2.2%. Top Headline U.S. retail sales increased 0.3% in August from July, versus a revised 0.4% decline in the prior month and topping market expectations for a flat reading. Equities Trading UP ZW Data Action Technologies Inc. (NASDAQ: CNET ) shares shot up 44% to $0.9549. ZW Data Action Technologies reported planned acquisition of Henan Baodun. Shares of NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO ) got a boost, shooting 36% to $22.96 after the company announced Dong-A has licensed its global exclusive development rights of DA-1241 for type 2 diabetes and non-alcoholic fatty hepatitis and DA-1726 for obesity and non-alcoholic fatty hepatitis to NeuroBo.
KMPH stock wins Buy rating at Canaccord on CNS focus (NASDAQ:KMPH) 2022/09/15 15:42:05 Seeking Alpha
Canaccord Genuity has launched its coverage on KemPharm, Inc
KemPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022/09/01 11:30:00 GlobeNewswire
CELEBRATION, Fla., Sept. 01, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and lysosomal storage diseases, today announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, will deliver a virtual presentation at the H.C. Wainwright 24 th Annual Global Investment Conference being held from September 12-14, 2022, in New York, New York. In addition, management will be available for virtual one-on-one investor meetings during the conference.